UCLA GP130 2

Pricing Availability   Qty
Description: gp130 agonist; brain penetrant and neuroprotectant
Chemical Name: N-(4-Fluorophenyl)-4-phenyl-2-thiazolamine
Purity: ≥98% (HPLC)
Literature (1)

Biological Activity for UCLA GP130 2

UCLA GP130 2 is a gp130 agonist. Protects against NMDA-induced toxicity in primary hippocampal neurons in vitro. Increases STAT3 phosphorylation in SH-SY5Y cells. Brain penetrant.

Compound Libraries for UCLA GP130 2

UCLA GP130 2 is also offered as part of the Tocriscreen 2.0 Max. Find out more about compound libraries available from Tocris.

Technical Data for UCLA GP130 2

M. Wt 270.32
Formula C15H11FN2S
Storage Store at +4°C
Purity ≥98% (HPLC)
CAS Number 339303-87-6
PubChem ID 1284592
Smiles FC1=CC=C(C=C1)NC2=NC(C3=CC=CC=C3)=CS2

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data for UCLA GP130 2

Solvent Max Conc. mg/mL Max Conc. mM
DMSO 27.03 100
ethanol 27.03 100

Preparing Stock Solutions for UCLA GP130 2

The following data is based on the product molecular weight 270.32. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 3.7 mL 18.5 mL 36.99 mL
5 mM 0.74 mL 3.7 mL 7.4 mL
10 mM 0.37 mL 1.85 mL 3.7 mL
50 mM 0.07 mL 0.37 mL 0.74 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

References for UCLA GP130 2

References are publications that support the biological activity of the product.

Alam et al (2018) A small molecule mimetic of the humanin peptide as a candidate for modulating NMDA-induced neurotoxicity. ACS Chem.Neurosci. 9 462 PMID: 29161500

If you know of a relevant reference for UCLA GP130 2, please let us know.

View Related Products by Target

View Related Products by Product Action

View all Cytokine Agonists

Keywords: UCLA GP130 2, UCLA GP130 2 supplier, UCLAGP1302, gp130, agonists, agonism, neuroprotectant, brain, penetrant, interleukin-6, receptor, beta, subunit, signal, transducer, humanin, Cytokines, 6583, Tocris Bioscience

Citations for UCLA GP130 2

Citations are publications that use Tocris products.

Currently there are no citations for UCLA GP130 2. Do you know of a great paper that uses UCLA GP130 2 from Tocris? Please let us know.

Reviews for UCLA GP130 2

There are currently no reviews for this product. Be the first to review UCLA GP130 2 and earn rewards!

Have you used UCLA GP130 2?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.

Rheumatoid Arthritis Poster

Rheumatoid Arthritis Poster

Rheumatoid arthritis (RA) is a chronic destructive inflammatory autoimmune disease that results from a breakdown in immune tolerance, for reasons that are as yet unknown. This poster summarizes the pathology of RA and the inflammatory processes involved, as well as describing some of the epigenetic modifications associated with the disease and the potential for targeting these changes in the discovery of new treatments.